NOV 24, 2015 12:08 PM PST

Brain Inflammation Linked to Persistant Depression Symptoms

WRITTEN BY: Kara Marker
A large number of people diagnosed with depression experience an inability to feel pleasure, and antidepressants don't seem to be helping. A new study from Emory Health Sciences has shown that inflammation in the brain is causing the disconnect, and anti-inflammatory drugs could reverse the effect.

"Anhedonia," also know as the loss in interest of previously pleasing activities like talking with friends, being outside or listening to music, is a common symptom of people with major depressive disorder (Psychology Today). Newly linked to inflammation, prior to this discovery doctors were unsure why antidepressants did not solve this problem associated with depression. 

In a study published this month in Molecular Psychiatry, scientists from Emory looked at brain images of 48 patients diagnosed with depression to investigate the potential of this "inflammatory depression." They analyzed the levels of c-reactive protein (CRP), an inflammatory marker produced by the liver in response to inflammation in the body (MedlinePlus). They collected brain images of their participants while they were not on any antidepressants or other drugs and compared the images to their CRP levels.
C-reactive protein

A clear connection was made between patients experiencing and reporting anhedonia and high levels of CRP circulating in their blood. In addition, brain images from these patients showed "low functional connectivity" between two regions of the brain related to motivation and reward. Patients with low levels of CRP did not report experiencing anhedonia and had normal connectivity between these brain regions.

"We were interested in these regions of the brain because of their known importance for response to reward," said lead author Jennifer Felger, PhD, assistant professor of psychiatry and behavioral sciences at Emory University School of Medicine and Winship Cancer Institute.

Scientists were also prompted to make this connection since decreased activity of the same two brain regions was seen in hepatitis C patients receiving "immuno-stimulatory" treatments that boosted inflammation. Scientists have begun using anti-inflammatory treatments for anhedonia patients and seen improvement. No change was seen in patients without anhedonia when given the same treatment. 

The next step, being pursued by the same group from Emory, is to test the effectiveness of L-DOPA therapy on anhedonia patients. L-DOPA therapy is currently used to treat Parkinson's disease by acting as a neurotransmitter and stimulating brain activity. 

Watch the following video to learn more about L-DOPA and how it works.

Source: Emory Woodruff Health Sciences Center
About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
SEP 07, 2019
Immunology
SEP 07, 2019
A New Way To Fight Severe Peanut Allergies
Dr. Sandra Lin explains how SLIT is currently being used to treat allergies other than peanuts.    Over 1 million U.S. children have an allergy t...
SEP 27, 2019
Immunology
SEP 27, 2019
Diseases We Share with Our Canine Companions: Autoimmune Encephalitis in Dogs
Like humans, dogs can develop autoimmune encephalitis, and it’s common - mostly affecting smaller breeds and young adult dogs. Now scientists underst...
NOV 10, 2019
Drug Discovery & Development
NOV 10, 2019
Promising Results for New Vaccine Against Dengue Fever
Dengue fever is an illness transmitted by mosquito bites. Affecting around 390 million people per year, if left untreated, its mortality rate is 20%. Altho...
JAN 22, 2020
Cancer
JAN 22, 2020
How the VISTA molecule affects immune responses
A new study describes how a molecule named VISTA has been impeding immune responses in cancer therapies. By turning this molecule “off,” resear...
FEB 06, 2020
Drug Discovery & Development
FEB 06, 2020
China Begins Trials for Antiviral Drug to Tackle Coronavirus
So far, coronavirus has infected over 31,493 people globally, and has killed 638. Although 1,563 people have reportedly recovered, due to its fast-spreadin...
FEB 07, 2020
Neuroscience
FEB 07, 2020
Eating Fruits and Vegetables May Lower Alzheimer's Risk
New research has found that flavonols, a large class of compounds present in many fruits and vegetables, may be linked to a lower risk of developing Alzhei...
Loading Comments...